Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Curocell's RIMQARTO (anbalcabtagene autoleucel) wins full South Korea approval for relapsed or refractory diffuse large B-cell lymphoma following Ph2 success
Cell therapy, cancer, CAR-T, diffuse large B-cell lymphoma, CD19, autologous T-cell therapy - Read more

Axsome Therapeutics' Auvelity (dextromethorphan/bupropion) receives FDA approval for agitation associated with Alzheimer's disease dementia
Small molecule, neurological, combination therapy, Alzheimer's disease, NMDA receptor antagonist, agitation - Read more

BeOne Medicines, Huahui Health strike $2B option deal for preclinical trispecific antibody HH160
Licensing deal, oncology, antibody, milestone payments, royalties - Read more

AstraZeneca licenses preclinical EGFR degrader from Pinetree Therapeutics for $25M, up to $500M milestones
Licensing deal, oncology, targeted protein degradation, small molecule, milestone payments, royalties - Read more

Formosa Pharmaceuticals, Singapore Eye Research Institute partner to advance ophthalmic formulations for corneal diseases
Research collaboration, Ophthalmology, Drug delivery, Small molecule, R&D - Read more

Guardant Health, Nuvalent collaborate on companion diagnostics for targeted cancer therapies
Research collaboration, Oncology, Diagnostics, Small molecule, Companion diagnostics - Read more

Cue Biopharma, Ascendant Health Sciences license anti-IgE antibody Ascendant-221, $15M upfront, $676.5M milestones
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

🚨 Applications are open for the 2026 Lilly Grand Challenge: Aging Reimagined

🔬 $100K in non-dilutive funding (no strings attached)
🏛️ A 2 day pitch at Lilly HQ in Indianapolis (all expenses paid)
🤝 Direct access to Lilly's scientific and venture teams

This year’s focus: Aging Reimagined — New Health Frontiers (mobility, cognition, immune resilience, regenerative medicine).

If you’re building in this space - or know someone who is - don’t miss this!

📅 Deadline: May 15

👉 Learn More and Apply Here: https://linktr.ee/lillygrandchallenge

Contineum Therapeutics' (PIPE-791) LPA1 antagonist shows positive Ph1b results in chronic osteoarthritis and low back pain
Small molecule, pain, LPA1 receptor antagonist, chronic pain, osteoarthritis - Read more

Merck & Co.'s Keytruda hits $8B in Q1 2025, with SC formulation Qlex gaining momentum
Monoclonal antibody, oncology, financial, strategic - Read more

Bristol Myers Squibb beats Q1 forecasts with Eliquis sales climbing 16% to $4.1B despite pricing headwinds
Small molecule, cardiovascular, revenue impact, competitive - Read more

Eli Lilly beats Q1 expectations with $19.8B revenue, raises full-year guidance
GLP-1 agonist, diabetes, financial, revenue impact - Read more

Alnylam Pharmaceuticals surpasses expectations as Amvuttra sales surge 187% to $889.9M in Q1
RNAi therapy, rare disease, revenue impact, financial - Read more

Myomaker Bio raises £325K ($443K) seed funding from SFC Capital for lab-grown human muscle platform
Bioengineered tissue, preclinical, drug discovery, platform technology - Read more

Valneva raises €84M ($98M) reserved offering to advance vaccine pipeline and commercial growth
Vaccines, infectious disease, clinical-stage - Read more

Ascendo Biotechnology closes Series A funding to advance innate immune checkpoint therapies
Innate immunity, oncology, antibody, clinical-stage - Read more

Iterative Health closes $77M Series C to expand clinical research network into new therapeutic areas
Clinical trial platform, CRO, AI-driven, gastroenterology - Read more

Moleculent raises $20M in funding, mapping cell-cell communication in human tissue
Spatial biology, platform technology, cell-cell communication, biomarker discovery - Read more

Novartis finalizes $23B US expansion with seventh facility, an API plant in North Carolina
Small molecule, RNA therapeutics, strategic, operational, manufacturing expansion - Read more

CareDx acquires Naveris for up to $260M, entering oncology with HPV cancer liquid biopsy platform
Liquid biopsy, oncology, strategic, major transaction - Read more

Leo Pharma acquires Replay for $50M, gaining preclinical HSV gene therapy platform for rare skin diseases
Gene therapy, rare disease, strategic, major transaction - Read more

EMA launches advisory group to combat growing vaccine hesitancy across Europe
Vaccine, infectious disease, strategic, operational - Read more

UniQure to seek UK approval for Huntington's gene therapy AMT-130, shares surge 20%
Gene therapy, neurological, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

AstraZeneca's (camizestrant) faces FDA panel rejection for estrogen receptor-mutated hormone receptor-positive, HER2-negative metastatic breast cancer in Ph3
Small molecule, cancer, oral SERD, breast cancer, ESR1 mutation, CDK4/6 inhibitor - Read more

Bristol Myers Squibb ends Zymeworks bispecific cancer collaboration, forgoing $313M in potential milestones
Partnership termination, Oncology, Bispecific antibody, Milestone payments, Solid tumors - Read more

Indivior's INDV-2000 (orexin-1 receptor antagonist) fails Ph2 primary endpoint for opioid use disorder treatment
Small molecule, neurological, orexin-1 receptor antagonist, opioid use disorder, buprenorphine - Read more

GSK, Alector's (nivisnebart) Ph2 trial halted in early Alzheimer's disease due to futility
Antibody, neurological, monoclonal antibody, Alzheimer's disease, frontotemporal dementia - Read more

FDA issues untitled letter to Bayer over misleading Nubeqa ads with distracting visuals
Small molecule, oncology, regulatory, operational - Read more

Amarox recalls UK batch of sertraline tablets after packaging mix-up includes wrong antidepressant
Small molecule, neurological, operational, safety - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here